Biomarker analyses provided proof of a mechanism during combination therapy.Yap and his colleagues observed increased CD8+ T cell infiltration and activation in tumors, reduced the regulatory T ...

Both Opdivo and Keytruda come as liquid solutions. The two drugs are given as an intravenous (IV) infusion, which is an injection into your vein given over a period of time. Infusions for both Opdivo ...

The U.S. Food and Drug Administration (FDA) has approved a new way to give pembrolizumab (brand name: Keytruda), one of the most widely used immunotherapy treatments for cancer. For the first time, ...

The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Merck & Co., Inc. is placed fourth among them. Merck & Co., Inc. (NYSE:MRK), a global ...

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American ...

PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...